Since synthetic PPARα and PPARγ agonistsindependently ameliorate obesity-induced inflammation, agoniststhat activate both PPARα and PPARγ (the so-calleddual PPARα/PPARγ agonists) might be even moreeffective. The gene discussed is PPARG; the disease is obesity disorder.